Terms: = Leukemia AND PDGFRA, MGC74795, 5156, ENSG00000134853, PDGFR2, CD140A, Rhe-PDGFRA, CD140a, P16234 AND Treatment
133 results:
1. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2024 May; 99(5):946-968. PubMed ID: 38551368
[TBL] [Abstract] [Full Text] [Related]
2. Integration of Genomic Sequencing Drives Therapeutic Targeting of pdgfra in T-Cell Acute Lymphoblastic leukemia/Lymphoblastic Lymphoma.
Paolino J; Dimitrov B; Apsel Winger B; Sandoval-Perez A; Rangarajan AV; Ocasio-Martinez N; Tsai HK; Li Y; Robichaud AL; Khalid D; Hatton C; Gillani R; Polonen P; Dilig A; Gotti G; Kavanagh J; Adhav AA; Gow S; Tsai J; Li Y; Ebert BL; Van Allen EM; Bledsoe J; Kim AS; Tasian SK; Cooper SL; Cooper TM; Hijiya N; Sulis ML; Shukla NN; Magee JA; Mullighan CG; Burke MJ; Luskin MR; Mar BG; Jacobson MP; Harris MH; Stegmaier K; Place AE; Pikman Y
Clin Cancer Res; 2023 Nov; 29(22):4613-4626. PubMed ID: 37725576
[TBL] [Abstract] [Full Text] [Related]
3. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion.
Zhang Y; Nguyen L; Lu CM; Wang E; Lauw MIS; Ball S; Dong N; Moscinski L; Chan O; Yun S; Sallman D; Sokol L; Shah B; Knepper T; Lancet J; Komrokji R; Padron E; Kuykendall A; Zhang L
Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):e150-e163. PubMed ID: 36624015
[TBL] [Abstract] [Full Text] [Related]
4. FIP1L1-pdgfra fusion gene in T-lymphoblastic lymphoma: A case report.
Ali S; Al-Qattan Y; Awny W; Hamadah A; Pinto K; AlShemmari S
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1769. PubMed ID: 36517458
[TBL] [Abstract] [Full Text] [Related]
5. Isocitrate dehydrogenase 1 mutation drives leukemogenesis by pdgfra activation due to insulator disruption in acute myeloid leukemia (AML).
Steinhäuser S; Silva P; Lenk L; Beder T; Hartmann A; Hänzelmann S; Fransecky L; Neumann M; Bastian L; Lipinski S; Richter K; Bultmann M; Hübner E; Xia S; Röllig C; Vogiatzi F; Schewe DM; Yumiceba V; Schultz K; Spielmann M; Baldus CD
Leukemia; 2023 Jan; 37(1):134-142. PubMed ID: 36411356
[TBL] [Abstract] [Full Text] [Related]
6. Two pediatric oncologic cases of hypereosinophilic syndrome and review of the literature.
Voeller J; DeNapoli T; Griffin TC
Cancer Rep (Hoboken); 2022 Nov; 5(11):e1710. PubMed ID: 36241191
[TBL] [Abstract] [Full Text] [Related]
7. A rare cause of persistent leukocytosis with massive splenomegaly: Myeloid neoplasm with BCR-pdgfra rearrangement-Case report and literature review.
Gao L; Xu Y; Weng LC; Tian ZG
Medicine (Baltimore); 2022 Jun; 101(24):e29179. PubMed ID: 35713428
[TBL] [Abstract] [Full Text] [Related]
8. Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/pdgfra axis.
Arribas AJ; Napoli S; Cascione L; Sartori G; Barnabei L; Gaudio E; Tarantelli C; Mensah AA; Spriano F; Zucchetto A; Rossi FM; Rinaldi A; Castro de Moura M; Jovic S; Bordone-Pittau R; Di Veroli A; Stathis A; Cruciani G; Stussi G; Gattei V; Brown JR; Esteller M; Zucca E; Rossi D; Bertoni F
Haematologica; 2022 Nov; 107(11):2685-2697. PubMed ID: 35484662
[TBL] [Abstract] [Full Text] [Related]
9. [Emergence of mutation in the colony-stimulating factor 3 receptor gene during follow-up of unclassifiable myeloproliferative neoplasm].
Harada S; Okada K; Yokoyama S; Hidaka D; Hayase E; Onozawa M; Goto H; Hashimoto D; Kahata K; Endo T; Teshima T
Rinsho Ketsueki; 2021; 62(11):1609-1614. PubMed ID: 34866084
[TBL] [Abstract] [Full Text] [Related]
10. Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent pdgfra amplification and loss of CDKN2A/B.
Deng MY; Sturm D; Pfaff E; Sill M; Stichel D; Balasubramanian GP; Tippelt S; Kramm C; Donson AM; Green AL; Jones C; Schittenhelm J; Ebinger M; Schuhmann MU; Jones BC; van Tilburg CM; Wittmann A; Golanov A; Ryzhova M; Ecker J; Milde T; Witt O; Sahm F; Reuss D; Sumerauer D; Zamecnik J; Korshunov A; von Deimling A; Pfister SM; Jones DTW
Nat Commun; 2021 Sep; 12(1):5530. PubMed ID: 34545083
[TBL] [Abstract] [Full Text] [Related]
11. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
[TBL] [Abstract] [Full Text] [Related]
12. FIP1L1-pdgfra-Associated Hypereosinophilic Syndrome as a Treatable Cause of Watershed Infarction.
Tennenbaum J; Groh M; Venditti L; Campos-Gazeau F; Chalayer E; De Broucker T; Hamidou M; Hunault M; Lyoubi A; Meunier R; Muron T; Sène D; Slama B; Guidoux C; Lefèvre G; Kahn JE; Denier C; Rohmer J
Stroke; 2021 Oct; 52(10):e605-e609. PubMed ID: 34304603
[TBL] [Abstract] [Full Text] [Related]
13. Venous thrombosis and predictors of relapse in eosinophil-related diseases.
Réau V; Vallée A; Terrier B; Plessier A; Abisror N; Ackermann F; Benainous R; Bohelay G; Chabi-Charvillat ML; Cornec D; Desbois AC; Faguer S; Freymond N; Gaillet A; Hamidou M; Killian M; Le Jeune S; Marchetti A; Meyer G; Osorio-Perez F; Panel K; Rautou PE; Rohmer J; Simon N; Tcherakian C; Vasse M; Zuelgaray E; Lefevre G; Kahn JE; Groh M
Sci Rep; 2021 Mar; 11(1):6388. PubMed ID: 33737704
[TBL] [Abstract] [Full Text] [Related]
14. Hypereosinophilic syndromes - An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment.
Helbig G; Klion AD
Blood Rev; 2021 Sep; 49():100809. PubMed ID: 33714638
[TBL] [Abstract] [Full Text] [Related]
15. The epigenetic treatment remodel genome-wide histone H4 hyper-acetylation patterns and affect signaling pathways in acute promyelocytic leukemia cells.
Valiulienė G; Vitkevičienė A; Navakauskienė R
Eur J Pharmacol; 2020 Dec; 889():173641. PubMed ID: 33045196
[TBL] [Abstract] [Full Text] [Related]
16. [Hypereosinophilic syndromes].
Groh M; Lefèvre G; Ackermann F; Étienne N; Kahn JE
Rev Prat; 2019 Sep; 69(7):767-773. PubMed ID: 32233322
[TBL] [Abstract] [Full Text] [Related]
17. The Efficacy of Imatinib Mesylate in the treatment of a Rare Lytic Bone Lesion Caused by Hypereosinophilic Syndrome/Chronic Eosinophilic leukemia: A Case Report.
Nomura H; Iwato K; Fujiwara M; Takano Y; Arima J
JBJS Case Connect; 2020; 10(1):e0126. PubMed ID: 32224679
[TBL] [Abstract] [Full Text] [Related]
18. Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines.
van Alphen C; Cloos J; Beekhof R; Cucchi DGJ; Piersma SR; Knol JC; Henneman AA; Pham TV; van Meerloo J; Ossenkoppele GJ; Verheul HMW; Janssen JJWM; Jimenez CR
Mol Cell Proteomics; 2020 May; 19(5):884-899. PubMed ID: 32102969
[TBL] [Abstract] [Full Text] [Related]
19. treatment-free remission in FIP1L1-pdgfra-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation.
Metzgeroth G; Schwaab J; Naumann N; Jawhar M; Haferlach T; Fabarius A; Hochhaus A; Hofmann WK; Cross NCP; Reiter A
Blood Adv; 2020 Feb; 4(3):440-443. PubMed ID: 31995156
[TBL] [Abstract] [Full Text] [Related]
20. [The 8p11 myeloproliferative syndrome: a review of recent literature].
Kirito K
Rinsho Ketsueki; 2019; 60(9):1157-1165. PubMed ID: 31597839
[TBL] [Abstract] [Full Text] [Related]
[Next]
